Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-02-05
1993-06-08
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514255, 514304, 514366, 514506, 514629, A61K 3140
Patent
active
052179877
ABSTRACT:
Mazindol and other nonreinforcing dopamine uptake inhibitors are effective to lessen craving for abused substances.
REFERENCES:
patent: 4786653 (1988-11-01), Golwyn
patent: 4919916 (1990-04-01), Golwyn
patent: 4935429 (1990-06-01), Dackis
L. D. Chait et al., Reinforcing and Subjective Effects of Several Anorectics in Normal Human Volunteers; 1987 vol. 242 pp. 777-783.
Prog. Neuropsychopharmacol. & Biol. Psychiat. 1988 (12) 233-239, "Cocaine Self Administration Appears to be Mediated by DA Uptake Inhibition".
Lif Sci. 1979(24) 159-168, "The Central Stimulatory Action of Inhibitors of DA Uptake".
Eur. J. Pharmacol. 1986(126) 211-222, "High Affinity [.sup.3 H]GBR 12783 Binding to a Specific Site Assoc. w/Neuronal DA Uptake Complex in the CNS".
"Dissociation of the Actions of Uptake Blockers on DA Overflow and Uptake in the Rat Nucleus Accumbens: In Vivo Voltammetric Data", AN=CA112(9):69849.
"Effects of Cocaine and Related Drugs in Nonhuman Primates", II AN=CA111(23):209081.
"Effects of Cocaine and Related Drugs in Nonhuman Primates", III AN=CA111(23) 209082.
"Circling induced by a DA Uptake Inhibitors", AN=CA91(7):49366.
F. H. Gawin et al., "An Open Trial of Mazindol to Treat Cocaine Craving in a Methadone Maintenance Clinic", Societ for Neuroscience 1988 Abstract Form, May 2, 1988.
The Lancet, Feb. 4, 1990, p. 283.
P. van der Zee et al., "Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake", Eur. J. Med. Chem, Jul.-Aug. 1980-15, No. 4, pp. 363-370.
K. Kumor et al., "Effects of Bromocriptine Pretreatment on Subjective and Physiological Responses to IV Cocaine", Pharmacology Biochemistry and Behavior, vol. 33, pp. 829-837, Pergamon Press, plc. 1980.
Physician's Desk Reference, Edition 43, p. 1571, 1989.
Angel et al., Brain Research, 503, pp. 339-341 (1989).
Zaczek et al., The Journal of Pharmacology and Expeimental Therapeutics, vol. 257, pp. 830-835 (1991).
Jaffe et al., "Potential Toxic Interactions of Cocaine and Mazindol", The Lancet, p. 111 (Jul. 8, 1989).
Tsung Frederick F.
Waddell Frederick E.
LandOfFree
Dopamine uptake inhibitors in reducing substance abuse and/or cr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dopamine uptake inhibitors in reducing substance abuse and/or cr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dopamine uptake inhibitors in reducing substance abuse and/or cr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1934305